Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-16569 |
Brand: | MCE |
CAS: | 64-86-8 |
MDL | - |
---|---|
Molecular Weight | 399.44 |
Molecular Formula | C22H25NO6 |
SMILES | CC(N[C@H](C1=C2)CCC3=CC(OC)=C(OC)C(OC)=C3C1=CC=C(OC)C2=O)=O |
Microtubule/Tubulin [1]
Exposure to 1μM Colchicine, a microtubule disrupting agent, triggered apoptosis in rat cerebellar granule cells (CGC). Colchicine treatment also causes alterations in Ca 2+ responses to chemical depolarization and a moderate, but progressive, increase in the resting intracellular Ca 2+ concentration [1] . Colchicine exerts its biological effects through binding to the soluble tubulin heterodimer, the major component of the microtubule. The Colchicine binding abilities of tubulins from a variety of sources are summarized, and the mechanism of Colchicine binding to brain tubulin is explored in depth. The relationship between colchicinoid structure and tubulin binding activity provides insight into the structural features of Colchicine responsible for high affinity binding to tubulin and is reviewed for analogs in the Colchicine series. The thermodynamic and kinetic aspects of the association are described and evaluated in terms of the binding mechanism. Colchicine binding to tubulin results in unusual alterations in the low energy electronic spectra of Colchicine. The spectroscopic features of Colchicine bound to tubulin are discussed in terms of the nature of the Colchicine-tubulin complex. Attempts to locate the high affinity Colchicine binding site on tubulin are presented [2] . Colchicine treatment inhibits indomethacin-induced small intestinal injury by 86% (1 mg/kg) and 94% (3 mg/kg) as indicated by the lesion index 24 h after indomethacin administration. Colchicine inhibits the protein expression of cleaved caspase-1 and mature IL-1β, without affecting the mRNA expression of NLRP3 and IL-1β [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Vehicle or Colchicine (1 mg/kg) is administered orally 30 min prior to indomethacin administration. The lesions stained with Evans blue in the small intestine are smaller in Colchicine-treated mice than those in vehicle-treated mice 24 h after indomethacin administration. In addition, histological examination shows that Colchicine-treated mice have less mucosal inflammation and ulceration and a decrease in the size and numbers of lesions compared with vehicle-treated mice. Colchicine treatment significantly reduces the lesion index at doses of 1 mg/kg and 3 mg/kg (by 86% and 94%, respectively) compared with vehicle treatment. Colchicine treatment significantly inhibits the protein levels of mature IL-1β at doses of 1 mg/kg and 3 mg/kg (by 56% and 69%, respectively) without affecting those of pro-IL-1β. Colchicine treatment also significantly inhibits the protein levels of cleaved caspase-1 at doses of 1 mg/kg and 3 mg/kg (by 26% and 39%, respectively) without affecting those of pro-caspase-1 [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04420624 | University Hospital, Montpellier |
Myocardial Infarction, Acute
|
December 4, 2020 | Phase 2|Phase 3 |
NCT04654416 | Clínica Medellín - Grupo Quirónsalud |
Covid-19
|
March 20, 2020 | |
NCT04328480 | Estudios Clínicos Latino América|Population Health Research Institute |
COVID-19
|
April 17, 2020 | Phase 3 |
NCT04381936 | University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding|NIHR Health Protection Research Unit in Emerging and Zoonotic Infections |
Severe Acute Respiratory Syndrome
|
March 19, 2020 | Phase 2|Phase 3 |
NCT05347316 | University of Sao Paulo General Hospital |
Atherosclerosis|Inflammatory Response|Coronary Disease
|
March 7, 2022 | Phase 1 |
NCT05168137 | Mahidol University|Thai AIDs society |
HIV Infections|Inflammatory Markers|Colchicine Adverse Reaction
|
February 1, 2020 | Phase 4 |
NCT03015831 | Jordan Collaborating Cardiology Group |
Atrial Fibrillation|Cardiac Surgery|Colchicine Adverse Reaction
|
October 2, 2017 | Phase 3 |
NCT04724629 | University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Science Valley Research Institute |
Covid19
|
January 5, 2021 | Phase 3 |
NCT05130892 | Wuhan Union Hospital, China |
NLRP3|hsCRP|Percutaneous Coronary Intervention
|
November 15, 2021 | Phase 4 |
NCT00370201 | Shahid Beheshti University of Medical Sciences |
Rhegmatogenous Retinal Detachment
|
March 2004 | Phase 3 |
NCT05159219 | Population Health Research Institute |
Intracranial Hemorrhages
|
August 4, 2022 | Phase 2 |
NCT05006001 | En Chu Kong Hospital |
Renal Impairment|Gout|Colchicine Adverse Reaction|Nonsteroidals (NSAIDs)Toxicity
|
January 1, 2012 | |
NCT04870424 | University Hospital Inselspital, Berne |
Transcatheter Aortic Valve Replacement|Atrial Fibrillation New Onset|Pacemaker|Colchicine
|
September 21, 2021 | Phase 3 |
NCT01399008 | CymaBay Therapeutics, Inc. |
Gout
|
June 2011 | Phase 2 |
NCT05246072 | Ain Shams University |
COVID-19
|
November 1, 2021 | Phase 4 |
NCT02551094 | Montreal Heart Institute |
Coronary Artery Disease|Myocardial Infarction
|
December 4, 2015 | Phase 3 |
NCT01552187 | Maria Vittoria Hospital |
Cardiac Surgery|Post-pericardiotomy Syndrome|Atrial Fibrillation|Pericardial Effusion|Pleural Effusion
|
March 2012 | Phase 3 |
NCT04056039 | Hospital Central Dr. Ignacio Morones Prieto |
Cardiovascular Diseases|Arthritis, Rheumatoid
|
August 14, 2018 | Phase 2 |
NCT00000577 | Milton S. Hershey Medical Center|National Heart, Lung, and Blood Institute (NHLBI) |
Asthma|Lung Diseases
|
September 1993 | Phase 3 |
NCT04527562 | Dhaka Medical College |
Covid19
|
July 14, 2020 | Not Applicable |
NCT04705987 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
HEART FAILURE
|
February 8, 2021 | Phase 3 |
NCT02624180 | Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI) |
Coronary Artery Disease|Human Immunodeficiency Virus
|
November 2015 | Phase 2 |
NCT04539873 | Fundación Universitaria de Ciencias de la Salud|Hospital de San Jose |
Corona Virus Infection
|
April 30, 2021 | Phase 3 |
NCT03131583 | Jiangsu HengRui Medicine Co., Ltd. |
Gout
|
February 17, 2017 | Phase 1 |
NCT05162742 | Radboud University Medical Center |
Aortic Valve Disease|Aortic Valve Stenosis|Aortic Valve Calcification|Inflammation|Calcification|Cardiovascular Diseases
|
November 1, 2022 | Phase 3 |
NCT04762771 | Baptist Health South Florida|University of California, Los Angeles |
Covid19
|
December 23, 2020 | Phase 1|Phase 2 |
NCT01416402 | CymaBay Therapeutics, Inc. |
Hyperuricemia|Gout
|
August 2011 | Phase 2 |
NCT00984061 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
November 2007 | Phase 1 |
NCT02281305 | G.Gennimatas General Hospital|Academy of Athens |
Acute Myocardial Infarction
|
October 2014 | Phase 4 |
NCT02153983 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Obesity|Metabolic Disease
|
May 31, 2014 | Phase 1|Phase 2 |
NCT02162303 | Montreal Heart Institute |
Atherosclerotic Vascular Disease
|
May 2014 | Phase 2 |
NCT04218786 | Shifa Tameer-e-Millat University|Rawalpindi Institute of Cardiology |
Myocardium; Injury|Myocardial Infarction|Myocardial Ischemia
|
December 2025 | Phase 2 |
NCT03310125 | Population Health Research Institute|Hamilton Health Sciences Corporation |
Atrial Fibrillation|Atrial Flutter
|
February 14, 2018 | Phase 3 |
NCT04139655 | University of British Columbia|Providence Health & Services|Vancouver Coastal Health |
Myocardial Infarction|Myocardial Injury|Major Adverse Cardiac Events|Infectious Complications
|
September 1, 2020 | Not Applicable |
NCT02128490 | Takeda |
Gout|Moderate Renal Impairment
|
May 2014 | Phase 2 |
NCT03704181 | University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Chagas Disease|Colchicine Resistance
|
October 1, 2018 | Phase 2 |
NCT05200052 | Ain Shams University |
Anterior MI|Colchicine
|
February 1, 2022 | Phase 4 |
NCT01336686 | CymaBay Therapeutics, Inc. |
Hyperuricemia|Gout
|
May 2011 | Phase 2 |
NCT04949516 | Wonkwang University Hospital |
Acute Coronary Syndrome|Drug-Eluting Stents
|
June 15, 2021 | Phase 4 |
NCT02095522 | Tel-Aviv Sourasky Medical Center|Tel Aviv Medical Center |
NSTEMI
|
March 2014 | Not Applicable |
NCT05017571 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) |
Obesity|Insulin Resistance|Inflammation
|
November 8, 2021 | Phase 2 |
NCT01017003 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
September 2007 | Phase 1 |
NCT01130051 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
May 2010 | Phase 1 |
NCT01001052 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
October 2009 | Phase 1 |
NCT01451645 | Regeneron Pharmaceuticals |
Intercritical Gout
|
October 2011 | Phase 4 |
NCT02252835 | CymaBay Therapeutics, Inc. |
Gout|Hyperuricemia
|
August 2014 | Phase 2 |
NCT05459974 | Stony Brook University |
Atrial Fibrillation
|
June 20, 2022 | Phase 3 |
NCT04818489 | ClinAmygate |
Covid19|Pulmonary Fibrosis Interstitial
|
March 25, 2021 | Phase 4 |
NCT05476991 | Assistance Publique - Hôpitaux de Paris |
Stroke|Stroke, Ischemic|Atherosclerosis|Myocardial Infarction|Coronary Syndrome|TIA|Cardiac Disease|Cerebral Infarction
|
September 1, 2022 | Phase 3 |
NCT04322565 | Azienda Ospedaliero-Universitaria di Parma |
Coronavirus Infections|Pneumonia, Viral
|
April 20, 2020 | Phase 2 |
NCT00983372 | Mutual Pharmaceutical Company, Inc. |
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
|
August 2008 | Phase 1 |
NCT00983515 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
July 2008 | Phase 1 |
NCT03735134 | Hillel Yaffe Medical Center |
Inflammation|Myocardial Infarction
|
November 2018 | Not Applicable |
NCT00128453 | Azienda Sanitaria Locale 3, Torino |
Pericarditis
|
August 2005 | Phase 3 |
NCT01017042 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
September 2007 | Phase 1 |
NCT03874338 | NYU Langone Health|Population Health Research Institute|National Heart, Lung, and Blood Institute (NHLBI) |
Neutrophils.Hypersegmented | Bld-Ser-Plas|STEMI - ST Elevation Myocardial Infarction
|
March 4, 2019 | |
NCT00983294 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
July 2008 | Phase 1 |
NCT03210610 | Sheba Medical Center |
FMF|Colchicine Resistance|Colchicine Toxicity
|
October 19, 2017 | |
NCT03693781 | Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute C. Mondino Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania Luigi Vanvitelli|Catholic University of the Sacred Heart |
Amyotrophic Lateral Sclerosis
|
April 10, 2019 | Phase 2 |
NCT04360980 | Shahid Beheshti University of Medical Sciences |
COVID-19
|
March 20, 2020 | Phase 2 |
NCT04601883 | Henning Bliddal|Frederiksberg University Hospital |
Osteoarthritis Hand|Osteoarthritis Finger
|
January 15, 2021 | Phase 4 |
NCT02594111 | VA Office of Research and Development|NYU Langone Health |
Coronary Artery Disease|Acute Coronary Syndrome
|
May 30, 2013 | Phase 4 |
NCT04403243 | Lomonosov Moscow State University Medical Research and Educational Center |
COVID 19
|
May 8, 2020 | Phase 2 |
NCT00960323 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
February 2009 | Phase 1 |
NCT04916522 | Herlev and Gentofte Hospital|University of Copenhagen |
Hypertension
|
August 10, 2021 | Phase 2 |
NCT00983931 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics|Healthy
|
August 2008 | Phase 1 |
NCT01173107 | Seoul National University Hospital |
Chronic Kidney Disease
|
December 2010 | Phase 4 |
NCT03048825 | Population Health Research Institute|Canadian Institutes of Health Research (CIHR)|Boston Scientific Corporation |
ST Elevation Myocardial Infarction|Non ST Elevation Myocardial Infarction
|
February 1, 2018 | Phase 3 |
NCT02260206 | Yong Seog Oh|Seoul St. Mary´s Hospital |
Pericardial Effusion
|
July 2014 | Phase 4 |
NCT00819585 | Novartis Pharmaceuticals|Novartis |
Gout
|
December 2008 | Phase 2 |
NCT05151614 | University of Baghdad |
COVID-19 Pandemic
|
April 1, 2021 | Phase 1 |
NCT04392141 | Kermanshah University of Medical Sciences |
COVID-19
|
April 1, 2020 | Phase 1|Phase 2 |
NCT04324463 | Population Health Research Institute|Bayer |
Coronavirus|Severe Acute Respiratory Syndrome
|
April 21, 2020 | Phase 3 |
NCT03156816 | Hospices Civils de Lyon |
Myocardial Infarction
|
July 23, 2018 | Phase 2 |
NCT04326790 | National and Kapodistrian University of Athens |
Corona Virus Disease 19 (Covid 19)
|
April 3, 2020 | Phase 2 |
NCT01709981 | NYU Langone Health|Takeda |
Coronary Artery Disease
|
May 30, 2013 | Phase 4 |
NCT04303689 | University of Copenhagen|University of Aarhus |
Essential Hypertension
|
August 1, 2020 | Not Applicable |
NCT01906749 | Maria Vittoria Hospital |
Acute Coronary Syndrome
|
June 2013 | Phase 4 |
NCT04355143 | University of California, Los Angeles |
COVID-19
|
May 1, 2020 | Phase 2 |
NCT02060552 | Tongji Hospital |
Primary Gout
|
January 2013 | Phase 4 |
NCT01075906 | Mutual Pharmaceutical Company, Inc. |
Familial Mediterranean Fever
|
August 2010 | Phase 1 |
NCT00128427 | Azienda Sanitaria Locale 3, Torino |
Postpericardiotomy Syndrome
|
June 2005 | Phase 3 |
NCT02926248 | Hospital for Special Surgery, New York |
Manipulation Under Anesthesia
|
May 2016 | Phase 4 |
NCT02035891 | Chongqing Medical University |
Diabetic Nephropathy
|
December 2013 | Not Applicable |
NCT00004368 | National Center for Research Resources (NCRR)|Children´s Hospital Colorado|Office of Rare Diseases (ORD) |
Cirrhosis|Liver Cirrhosis
|
May 1990 | Phase 1 |
NCT02063997 | CymaBay Therapeutics, Inc. |
Gout
|
March 2014 | Phase 2 |
NCT04756128 | HealthPartners Institute|Park Nicollet Foundation |
Covid19
|
January 25, 2021 | Phase 2 |
NCT01935700 | Kaohsiung Medical University Chung-Ho Memorial Hospital |
Hepatocellular Carcinoma|Metastasis|Invasion
|
June 6, 2013 | Phase 2 |
NCT01040845 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
August 2007 | Phase 1 |
NCT01994226 | Keele University |
Gout
|
January 2014 | Phase 4 |
NCT00983242 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
September 2008 | Phase 1 |
NCT01021020 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
September 2007 | Phase 1 |
NCT05618353 | VA Office of Research and Development|NYU School of Medicine |
Coronary Artery Disease
|
May 1, 2023 | Phase 4 |
NCT04492358 | Maria Joyera Rodríguez|Fundacion Clinic per a la Recerca Biomédica |
Covid19
|
October 22, 2020 | Phase 2|Phase 3 |
NCT04382443 | Centro de estudios en Cardiologia Intervencionista |
Coronary Artery Disease|Restenosis of Coronary Artery Stent|Atherosclerosis|Acute Coronary Syndrome
|
March 12, 2020 | Phase 4 |
NCT03575572 | University of Michigan |
Single-ventricle|Heart Diseases
|
August 29, 2018 | Phase 2|Phase 3 |
NCT00983216 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
July 2008 | Phase 1 |
NCT05361772 | Guangdong Provincial People´s Hospital|The First Affiliated Hospital of Guangzhou Medical University|Shenzhen People´s Hospital|Peking University Shougang Hospital|Peking Union Medical College Hospital|The Second Xianya Hospital of Central South University|Zhongshan People´s Hospital, Guangdong, China|Shenzhen Bao an People´s Hospital |
Colchicine|Abdominal Aortic Aneurysm|Progression
|
June 1, 2022 | Not Applicable |
NCT03226899 | Ironwood Pharmaceuticals, Inc.|Medpace, Inc. |
Gout|Chronic Kidney Disease (CKD)
|
July 19, 2017 | Phase 4 |
NCT00960193 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
February 2009 | Phase 1 |
NCT01601132 | Takeda |
Healthy
|
May 2012 | Phase 4 |
NCT01084278 | Takeda |
Pharmacokinetics
|
May 2010 | Phase 4 |
NCT01112982 | University of South Florida|Takeda Pharmaceuticals North America, Inc. |
Gout
|
May 2010 | Phase 4 |
NCT04264260 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Medical University |
Hepatocellular Carcinoma Stage IIIB|Cholangiocarcinoma, Intrahepatic|Cholangiocarcinoma; With Hepatocellular Carcinoma|Hepatocellular Carcinoma Stage IV
|
December 24, 2019 | Phase 2 |
NCT00723268 | Mashhad University of Medical Sciences|University of Tehran |
Oral Aphthae
|
May 2007 | Phase 2 |
NCT02175589 | Rambam Health Care Campus|Schneider Children´s Hospital |
Familial Mediterranean Fever
|
June 2014 | Phase 2 |
NCT04130204 | Dyve Biosciences, Inc. |
Gout
|
February 12, 2020 | Phase 2 |
NCT04867226 | Hawler Medical University |
Coronavirus Infection
|
May 8, 2021 | Phase 2 |
NCT03376698 | University of the Ryukyus |
Colchicine|Diabetes Mellitus, Type 2|Coronary Artery Disease|White Blood Cell|Inflammation|Diarrhea
|
June 15, 2017 | Phase 2 |
NCT04416334 | Instituto de Investigación Marqués de Valdecilla|Gerencia de atención primaria área 1|Gerencia de atención primaria área 2|Gerencia Atencion Primaria Area 3|Gerencia de atención primaria área 4 |
SARS-CoV-2 Infection (COVID-19)
|
August 19, 2020 | Phase 3 |
NCT05503225 | Chinese University of Hong Kong |
ICAD - Intracranial Atherosclerotic Disease
|
September 1, 2022 | Phase 2 |
NCT04697602 | National Taiwan University Hospital|National Taiwan University Hospital, Yun-Lin Branch |
Gout
|
January 20, 2021 | Not Applicable |
NCT05118737 | Hamad Medical Corporation |
COVID-19 Pneumonia
|
October 1, 2021 | Early Phase 1 |
NCT05175274 | Qingdao Central Hospital|Qingdao Municipal Hospital |
Coronary Artery Disease
|
December 6, 2022 | Phase 3 |
NCT00506883 | Takeda |
Gout
|
April 2007 | Phase 3 |
NCT02330796 | Revive Therapeutics, Ltd. |
Gout
|
April 2015 | Phase 2 |
NCT05418686 | Assistance Publique - Hôpitaux de Paris |
Mediterranean Fever|Colchicine Resistance
|
July 2022 | Not Applicable |
NCT02083510 | Scripps Translational Science Institute |
Hypertriglyceridemia|Gout|Pericarditis
|
February 2014 | Early Phase 1 |
NCT02500641 | Menarini International Operations Luxembourg SA |
Gout
|
August 17, 2015 | Phase 4 |
NCT03905759 | doaa rashwan|Beni-Suef University |
Postoperative Atrial Fibrillation
|
April 3, 2019 | Phase 2|Phase 3 |
NCT01985425 | Population Health Research Institute|Canadian Institutes of Health Research (CIHR) |
Atrial Fibrillation|Thoracic Surgery
|
April 2014 | Phase 3 |
NCT04516941 | University Hospital Inselspital, Berne|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
SARS-CoV Infection|COVID-19
|
January 21, 2021 | Phase 3 |
NCT05250596 | Azienda USL Toscana Centro |
Non ST Segment Elevation Acute Coronary Syndrome
|
February 24, 2022 | Phase 2 |
NCT01481233 | Milton S. Hershey Medical Center |
Prostate Cancer
|
May 2013 | Phase 2 |
NCT04857931 | Montreal Heart Institute |
Heart Failure|Inflammation|Colchicine
|
June 17, 2022 | Phase 2 |
NCT01936285 | G.Gennimatas General Hospital |
Acute Myocardial Infarction
|
July 2013 | Phase 4 |
NCT04377321 | Ministry of Health and Population, Egypt |
Treatment Adherence
|
October 10, 2019 | |
NCT01018420 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
November 2007 | Phase 1 |
NCT00004748 | National Center for Research Resources (NCRR)|Tufts Medical Center|Office of Rare Diseases (ORD) |
Liver Cirrhosis, Biliary
|
November 1989 | Phase 3 |
NCT02366091 | Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI) |
Coronary Artery Disease
|
January 2015 | Phase 2 |
NCT02282098 | Population Health Research Institute |
Atrial Fibrillation|Stroke
|
November 2014 | Phase 3 |
NCT05038449 | Shanghai Public Health Clinical Center|Kunming Pharmaceuticals, Inc. |
Covid19|Colchicine
|
September 6, 2021 | Not Applicable |
NCT02139046 | Takeda |
Gout
|
April 2014 | Phase 3 |
NCT04906720 | St. Vincent Cardiovascular Research Institute |
Atrial Fibrillation|Catheter Ablation|Pericarditis
|
May 20, 2021 | Phase 2 |
NCT02176460 | Singapore General Hospital|Duke University|Duke-NUS Graduate Medical School |
Knee Osteoarthritis
|
October 2013 | Phase 2|Phase 3 |
NCT04224545 | Bakulev Scientific Center of Cardiovascular Surgery |
Colchicine Adverse Reaction|Atrial Fibrillation New Onset
|
December 23, 2019 | Phase 4 |
NCT04322682 | Montreal Heart Institute|National Heart, Lung, and Blood Institute (NHLBI)|Bill and Melinda Gates Foundation|The Government of Quebec|DACIMA Software |
Corona Virus Infection
|
March 23, 2020 | Phase 3 |
NCT00840489 | Hospital Universitario Ramon y Cajal |
Chronic Hepatitis C
|
January 2009 | Phase 2 |
NCT04355585 | Brigham and Women´s Hospital|Harvard Medical School (HMS and HSDM) |
Colchicine Mechanism of Action
|
May 6, 2020 | Phase 1 |
NCT00179413 | Beth Israel Deaconess Medical Center|Schering-Plough |
Hepatitis C Virus|Advanced Fibrosis|Cirrhosis
|
January 15, 2000 | Phase 4 |
NCT00235079 | Azienda Sanitaria Locale 3, Torino |
Pericarditis|Recurrence
|
November 2005 | Phase 4 |
NCT04848857 | Wuhan Union Hospital, China |
Acute Coronary Syndrome
|
May 3, 2021 | Phase 4 |
NCT05253794 | Ottawa Heart Institute Research Corporation |
Aortic Stenosis|Inflammation
|
July 1, 2022 | Phase 2|Phase 3 |
NCT02995512 | NYU Langone Health |
Myocardial Infarction
|
May 1, 2017 | Phase 4 |
NCT02177266 | Mayo Clinic |
Atrial Fibrillation|Post-pericardiotomy Syndrome|Constriction
|
May 2015 | Phase 3 |
NCT02939573 | University of Pennsylvania|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Center for Advancing Translational Sciences (NCATS)|Office of Rare Diseases (ORD) |
Primary Cutaneous Vasculitis|Cutaneous Polyarteritis Nodosa|IgA Vasculitis|Henoch-Schönlein Purpura
|
January 1, 2017 | Phase 2 |
NCT00983905 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
August 2008 | Phase 1 |
NCT00700297 | Tehran University of Medical Sciences |
Behcet´s Syndrome
|
August 2002 | Phase 2 |
NCT01005121 | Prof.Avi Livneh|Sheba Medical Center |
Diabetic Nephropathy
|
December 2009 | Phase 2 |
NCT04363437 | Maimonides Medical Center |
Coronavirus Infection
|
April 26, 2020 | Phase 2 |
NCT05279690 | Icahn School of Medicine at Mount Sinai |
Urothelial Cancer|Metastatic Solid Tumor
|
February 14, 2022 | Phase 1 |
NCT03888846 | Ipekyolu Ilac Ltd. Sti|Istanbul University-Cerrahpasa School of Medicine |
Behçet Disease Affecting Oral Mucosa
|
March 25, 2019 | Phase 2 |
NCT02898610 | University College Dublin|Health Research Board, Ireland|Irish Heart Foundation|University of Limerick|University of Edinburgh|National University of Ireland, Galway, Ireland|Universitat de Lleida|Universitaire Ziekenhuizen KU Leuven|University of Athens |
Ischemic Attack, Transient|Stroke
|
December 12, 2016 | Phase 3 |
NCT04181996 | Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR) |
Cardiovascular Diseases|Atherosclerosis|Inflammation|Diabetes
|
August 1, 2020 | Phase 3 |
NCT03659058 | Zagazig University |
Fibrosis, Liver
|
March 2, 2016 | Not Applicable |
NCT02442921 | Sheba Medical Center|D-Cure, Israel |
Diabetic Nephropathies
|
February 22, 2016 | Phase 1|Phase 2 |
NCT04008316 | Assistance Publique - Hôpitaux de Paris |
IgA Vasculitis
|
November 12, 2019 | Phase 3 |
NCT02582190 | Elpen Pharmaceutical Co. Inc. |
Atrial Fibrillation
|
December 2, 2017 | Phase 3 |
NCT03913442 | NYU Langone Health |
Osteoarthritis|Osteo Arthritis Knee
|
May 15, 2019 | Phase 4 |
NCT04350320 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
COVID19
|
April 30, 2020 | Phase 3 |
NCT00983177 | Bnai Zion Medical Center |
Calcific Tendonitis
|
March 2010 | Not Applicable |
NCT04160117 | Population Health Research Institute |
Atrial Fibrillation|Recurrence
|
January 14, 2020 | Phase 3 |
NCT05472337 | Pontificia Universidad Catolica de Chile|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile |
Acute Coronary Syndrome
|
August 1, 2022 | Phase 2 |
NCT00128414 | Azienda Sanitaria Locale 3, Torino |
Pericarditis|Recurrence
|
August 2005 | Phase 3 |
NCT05324423 | The Affiliated Hospital of Qingdao University |
Gout
|
October 18, 2021 | Phase 1 |
NCT04500665 | Brigham and Women´s Hospital|National Heart, Lung, and Blood Institute (NHLBI) |
Chronic Kidney Diseases
|
November 1, 2021 | Phase 2 |
NCT04774159 | Population Health Research Institute |
Peripheral Arterial Disease|Atherosclerosis of Extremities|Inflammation
|
May 6, 2021 | Phase 3 |
NCT05439356 | Beijing Tiantan Hospital |
Ischemic Stroke|TIA
|
August 10, 2022 | Phase 3 |
NCT04155879 | Hillel Yaffe Medical Center |
Atrial Fibrillation
|
November 2019 | Not Applicable |
NCT03128905 | Lille Catholic University|University Hospital, Lille|Hopital Lariboisière|Bichat Hospital|Valenciennes Hospital Centre|Armentières Hospital Centre|Dunkerque Hospital Centre |
Chondrocalcinosis
|
February 5, 2018 | Phase 3 |
NCT04359095 | Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Colsanitas-Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia (HUN)|Fundación Cardioinfantil Instituto de Cardiología|Clínica Infantil Santa María del Lago |
COVID-19
|
August 18, 2020 | Phase 2|Phase 3 |
NCT00984009 | Mutual Pharmaceutical Company, Inc. |
Pharmacokinetics
|
September 2008 | Phase 1 |
NCT03021343 | Jordan Collaborating Cardiology Group |
Arrhythmia
|
October 2012 | Phase 3 |
NCT02122484 | G.Gennimatas General Hospital|Evangelismos Hospital |
Elective Coronary Artery Bypass Graft Surgery
|
November 2013 | Phase 4 |
NCT04367168 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
COVID
|
May 27, 2020 | Phase 2 |
NCT01123395 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
May 2010 | Phase 1 |
NCT04375202 | University Of Perugia |
COVID-19
|
April 18, 2020 | Phase 2 |
NCT05335148 | Rutgers, The State University of New Jersey |
Radiation Therapy
|
May 10, 2022 | Phase 1 |
NCT02140372 | NYU Langone Health |
Healthy
|
May 2014 | Phase 4 |
NCT02602028 | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi |
Familial Mediterranean Fever
|
April 2011 | Phase 4 |
NCT00754819 | Hamilton Health Sciences Corporation|McMaster University |
Acute Coronary Syndrome
|
April 2008 | Phase 2|Phase 3 |
NCT04667780 | Ayub Teaching Hospital|Universidad de Murcia |
COVID-19
|
December 1, 2020 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 48 mg/mL ( 120.17 mM )
H 2 O : ≥ 33.33 mg/mL ( 83.44 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.5035 mL | 12.5175 mL | 25.0350 mL |
5 mM | 0.5007 mL | 2.5035 mL | 5.0070 mL |
10 mM | 0.2504 mL | 1.2518 mL | 2.5035 mL |
Add each solvent one by one: PBS
Solubility: 2.78 mg/mL (6.96 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.